Bicycle Therapeutics Recognised With Multiple Biotech Industry Awards

– Named by Biotech and Money as the Private Life Science Growth Company of the Year –

– Wins Best Platform Technology category at the World ADC Awards –

CAMBRIDGE, England & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, today announced that it has been recognised by Biotech and Money, a community of senior life science decision makers, as the Private Life Science Growth Company of the Year. In addition, the company received the award of Best Platform Technology at the World ADC Awards. Presented during the World ADC Conference, the award acknowledges the best linker or payload platform technology and is selected for the system’s novelty and originality as well as scientific and commercial validation of the platform.

“We are honoured to be recognised by Biotech and Money and the World ADC Conference for our progress in pioneering our innovative new class of therapies for cancer and other diseases of high unmet need,” said Kevin Lee, Ph.D., Bicycle’s Chief Executive Officer. “Our team is working with urgency to advance our deep and robust pipeline of Bicycles, including our lead molecule BT1718, which will enter clinical development in partnership with Cancer Research UK in the near future. These awards are a testament to our efforts, and to the great potential for Bicycles to transform the treatment paradigm for patients with cancer and other hard to treat diseases.”

Bicycles are a brand new class of chemically synthesised molecules designed to rapidly and selectively penetrate tumours while minimising exposure to healthy tissue. They are cleared quickly by the kidneys; avoiding liver toxicity often associated with other drug classes. Bicycles can be used as stand-alone therapeutic entities, as tandem or multimeric Bicycles to modulate more than one target, or chemically coupled to deliver a variety of payloads.

In addition to these two awards, Bicycle’s scientific founder, Sir Gregory Winter, received an award for individual input to the drug conjugate field in 2016 at the World ADC awards. Bicycle has also been named a finalist in three categories for the 2017 Scrip Awards, which will be announced on November 29.

“I am delighted to be recognized by the World ADC conference for my contributions to Bicycle Therapeutics,” said Sir Gregory Winter, one of Bicycle’s scientific founders. “Using low molecular weight, bicyclic peptides for the targeted delivery of toxic payloads is an exciting application of this technology and I look forward to seeing the clinical data.”

About Bicycle Therapeutics

Bicycle Therapeutics is developing a new class of medicines to treat oncology and other important diseases based on its proprietary bicyclic peptide (Bicycle®) product platform. Bicycles® exhibit the affinity and exquisite target specificity usually associated with antibodies. Their small size enables rapid and deep tissue penetration, allowing tissues and tumours to be targeted from within. Their peptidic nature provides a “tuneable” pharmacokinetic half-life and a renal route of clearance, thus avoiding the liver and gastrointestinal tract toxicity often seen with other drug modalities. Bicycle Therapeutics is rapidly advancing towards the clinic with its lead programs using Bicycle Drug Conjugates® to selectively deliver toxins to tumours. Bicycle Therapeutics is collaborating in oncology and other areas to realise the full potential of the technology. Bicycle Therapeutics’ unique intellectual property is based on the work initiated at the MRC Laboratory of Molecular Biology in Cambridge, U.K., by the scientific founders of the company, Sir Gregory Winter and Professor Christian Heinis. Bicycle Therapeutics is headquartered in Cambridge, U.K., with a U.S. subsidiary in Cambridge, Massachusetts. For more information, visit

Ten Bridge Communications (U.S.)
Sarah Sutton, +1-518-932-3680
Consilium Strategic Communications (EU)
Mary-Jane Elliott / Chris Gardner / Ivar Milligan, +44 20 3709 5700

Back to news